Biliary Anomalies in Patients With HNF1B Diabetes

Kettunen, Jarno L. T.

2017-06


http://hdl.handle.net/10138/198893
https://doi.org/10.1210/jc.2017-00061

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.
Biliary Anomalies in Patients With HNF1B Diabetes

Jarno L. T. Kettunen,1,2 Helka Parviainen,3 Päivi J. Miettinen,4 Martti Färkkilä,5 Marjo Tamminen,6 Pia Salonen,7 Eila Lantto,3 and Tiinamaija Tuomi1,2,8

1Department of Endocrinology, Abdominal Centre, Helsinki University Hospital, Helsinki 00029, Finland; 2Folkhalsan Research Center; and Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki 00014, Finland; 3HUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki 00029, Finland; 4Children’s Hospital, University of Helsinki, and Helsinki University Hospital, Helsinki 00029, Finland; 5University of Helsinki, Department of Gastroenterology, Abdominal Centre, and Helsinki University Hospital, Helsinki 00029, Finland; 6Department of Internal Medicine, Central Hospital of Kymenlaakso, Kotka 48210, Finland; 7Department of Pediatrics, Central Hospital of Päijät-Häme, Lahti 15850, Finland; and 8Institute for Molecular Medicine Finland, University of Helsinki, Helsinki 00014, Finland

Context: The clinical spectrum of organogenetic anomalies associated with HNF1B mutations is heterogeneous. Besides cystic kidney disease, diabetes, and various other manifestations, odd cases of mainly neonatal and posttransplantation cholestasis have been described. The biliary phenotype is incompletely defined.

Objective: To systematically characterize HNF1B-related anomalies in the bile ducts by imaging with magnetic resonance imaging (MRI) or magnetic resonance cholangiopancreatography (MRCP).

Setting and Patients: Fourteen patients with HNF1B mutations in the catchment area of the Helsinki University Hospital were evaluated with upper abdominal MRI and MRCP. Blood samples and clinical history provided supplemental data on the individual phenotype.

Main Outcome Measure(s): Structural anomalies in the biliary system, medical history of cholestasis, other findings in abdominal organs, diabetes and antihyperglycemic treatment, hypomagnesemia, and hyperuricemia.

Results: Structural anomalies of the bile ducts were found in seven of 14 patients (50%). Six patients had choledochal cysts, which are generally considered premalignant.

Conclusions: Structural anomalies of the biliary system were common in HNF1B mutation carriers. The malignant potential of HNF1B-associated choledochal cysts warrants further studies. (J Clin Endocrinol Metab 102: 2075–2082, 2017)

Hepatocyte nuclear factor 1B (HNF1B) is a key regulator of mammalian organogenesis that is particularly required for specification of the pancreas and other organs derived from the ventral endoderm (1–5). Autosomal-dominantly inherited mutations in the HNF1B gene lead to a spectrum of clinical manifestations. HNF1B mutations rank as the most common monogenic cause of kidney and urinary tract anomalies, with renal function ranging from normal to end-stage renal disease (6), but kidneys can, nevertheless, appear normal in imaging studies (7). Approximately half of patients with HNF1B mutations develop maturity-onset diabetes of the young (MODY) at an age ranging from the neonatal period to adulthood, apparently as a result of pancreatic hypoplasia and impaired insulin secretion, in combination with hepatic insulin resistance (7–11). The heterogeneous extrarenal manifestations also include hypomagnesemia (12), hyperuricemia, early-onset gout
(13, 14), genital malformations (15–17), elevated liver enzymes (14, 18), impaired exocrine pancreatic function (19), and increased parathyroid hormone levels with reduced urinary calcium excretion (20). In addition, larger microdeletions in chromosome 17q12 harboring **HNF1B** result in neurologic and behavioral symptoms (21). **De novo** mutations occur in approximately half of the affected persons (9).

**HNF1B** is involved in biliary system organogenesis, and conditional deletion of **HNF1B** in mice leads to severe jaundice, a paucity of small intrahepatic bile ducts, and abnormalities of the gallbladder (22). In humans, data on the possible biliary or hepatic clinical phenotype of **HNF1B** disease are scarce (23–25). Seven case reports have presented patients with either cholestasis or mainly cholestatic liver function tests (25). A few liver biopsies in neonates with cholestasis showed a paucity of bile ducts and ductal plate malformations with duct dysplasia (23–26). Electron microscopy revealed cholangiocytes with fewer primary cilia in biopsies from three adults whose routine liver pathology appeared normal (27). Bile duct imaging is rare in patients with **HNF1B** disease. In endoscopic retrograde cholangiopancreatography (ERCP), one patient had extrahepatic biliary atresia that was confirmed by surgery, and on magnetic resonance imaging (MRI), one patient had slightly dilated intra- and extrahepatic bile ducts (25, 28). A few studies provide a limited number of patients who have undergone abdominal MRI (11, 28). No study has specifically focused on bile duct imaging.

Here, by use of contrast-enhanced MRI and magnetic resonance cholangiopancreatography (MRCP), noninvasive imaging modalities for hepatic and pancreaticobiliary pathologies, we report biliary abnormalities in patients with **HNF1B** mutations.

**Patients and Methods**

In the catchment area of Helsinki University Hospital, 14 patients from the Botnia Study (www.botnia-study.org) or the FinnMODY Study (www.botnia-study.org/finnmody) with **HNF1B** mutations underwent upper abdominal MRI and MRCP imaging as part of their clinical follow-up. The Botnia Study has been recruiting families with diabetes from Finland since 1990, and its extension, the FinnMODY Study, has been recruiting patients with diagnosed or possible MODY, as well as their family members, since 2014. The studies followed the principles of the Declaration of Helsinki and were approved by the local ethics committee, with informed consent from all study participants.

Nine patients had a whole-allele deletion of **HNF1B**, and five patients (nos. 3, 4, 5, 6, and 13) had heterozygous intragenic mutations. The intragenic mutations comprised a splice site mutation in one patient, a nonsense mutation in another patient, and nonconservative missense mutations in three patients.

Of the 14 patients (11 females, three males; age 10 to 68 years at imaging), 13 were diagnosed with diabetes at a median age of 23 years (range, 6 to 54 years; one patient was diagnosed during posttransplantation immunosuppressive treatment). One remained normoglycemic at the age of 22. Eight patients were treated with insulin, and the rest used no anti-hyperglycemic medication (Table 1). Data for glycosylated hemoglobin (HbA1c), serum or plasma concentration of alanine aminotransferase (ALT), uric acid, magnesium, creatinine, and cystatin C came from hospital records or the Botnia and FinnMODY Studies. Glomerular filtration rate was estimated in adults by the Chronic Kidney Disease Epidemiology Collaboration equation on the basis of creatinine only, and in children by the Chronic Kidney Disease in Childhood (CKiD) Schwartz equation on the basis of creatinine, blood urea nitrogen, and cystatin C.

Two authors (H.P. and E.L.) interpreted the MRI scans performed from 2003 to 2016 to evaluate the morphology of the biliary system and other abdominal organs. Cystic or fusiform dilatations of the bile ducts [bile duct cysts (BDCs), also known as choledochal cysts] were grouped according to the Todani classification, if applicable (29). All scans were performed with 1.5-T whole-body scanners; gadolinium-enhanced sequences were available in 12 and MRCP sequences in 11 patients. In addition, genital morphology of female patients was evaluated by MRI (nine patients), transabdominal ultrasonography (one patient), or abdominal computed tomography scan (two patients), depending on availability. Table 1 demonstrates the imaging summary of the patients.

The genetic testing included next-generation sequencing confirmed with direct sequencing and/or multiplex ligation-dependent probe amplification dosage analysis of the **HNF1B** gene in two service laboratories (the Molecular Genetics Laboratory in Exeter, United Kingdom, or the Genome Center of Eastern Finland). The genetic diagnosis of one patient with a whole-gene deletion was made through molecular karyotyping analysis performed at the laboratory of the Helsinki University Hospital.

**Results**

Seven of the 14 patients demonstrated bile duct anomalies on MRI (Figs. 1–2; Table 1). Five patients had varying types of BDCs in the extrahepatic bile ducts and gallbladder, whereas one patient had a 25-mm-wide intrahepatic BDC communicating with the left main hepatic duct (Fig. 1). In two patients (nos. 12 and 14), we observed small diverticula in the wall of the gallbladder fundus consistent with adenomyomatosis. Patient no. 1 had undergone a BDC resection and Roux-en-Y hepaticojejunostomy at the age of 12 years for an incidental BDC, and although slight widening of the proximal intrahepatic bile ducts could be detected in the preoperative MRI scan (Fig. 1), in the postoperative MRI scans, the intrahepatic finding was normal (data not shown). In addition, patient no. 13 had experienced occasional episodes of unpecific upper abdominal pain before receiving a kidney transplantation at the age of 30, but profound abdominal symptoms with cholestatic liver function tests emerged after transplantation. Posttransplantation imaging revealed moderate dilatation of extrahepatic and
proximal intrahepatic bile ducts caused by a papillary tumorlike mass, which by subsequent ERCP imaging and biopsies proved to be benign adenoma.

The liver parenchyma appeared normal in all cases; one patient had a small subcapsular cyst, which is a common incidental finding in the general population as well (Table 1). Nevertheless, seven patients had abnormal serum ALT levels, which were generally less than twice the upper reference limit. However, after major abdominal surgery (patient no. 1) or renal transplantation (patients no. 6 and 13), ALT had transiently exceeded the upper reference limit by 24-fold.

Most patients (12 of 14) had a hypoplastic pancreas: nine had a hypoplasia of the body and tail of the pancreas, whereas three patients lacked only the tail (Table 1; Fig. 3). One patient had small calcifications in the pancreatic parenchyma. The radiological findings did not correlate with the severity of diabetes. Two patients with normal pancreas on imaging had mild diabetes without treatment (age 10 and 27 years; HbA1c, 32 and 36 mmol/mol, respectively). Of the 12 patients with hypoplastic pancreatic findings, the degree of glycemia varied from normal (one 22-year-old patient had HbA1c of 35 mmol/mol) to diabetic, and therapy ranged from none in four patients (age 12 to 22 years; HbA1c, 33 to 44 mmol/mol) to insulin in eight patients (age 14 to 68 years; HbA1c, 35 to 92; median HbA1c, 48 mmol/mol) (Table 1).

The pancreatic duct was of normal caliber in all patients, albeit shorter than usual in patients who had pancreatic hypoplasia. Patient no. 12 had the normal variant of pancreas divisum, in which the ventral and dorsal pancreatic ducts have not fused during embryonic development (Table 1). Patients no. 7 and 14 had small cystic dilatations of the pancreatic branch ducts; the MRI

Table 1. Patient Clinical Characteristics and Imaging Findings

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (Sex)</th>
<th>Bile Ducts</th>
<th>Liver</th>
<th>Pancreatic Hypoplasia</th>
<th>Kidneys</th>
<th>Renal Insufficiency</th>
<th>Uterus</th>
<th>Insulin Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12 (F)</td>
<td>EH BDC</td>
<td>N</td>
<td>Tail, body</td>
<td>Multiple cysts</td>
<td>No</td>
<td>Bicornuate unicollis</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>14 (M)</td>
<td>N</td>
<td>N</td>
<td>Tail, body</td>
<td>One cyst</td>
<td>No</td>
<td>—</td>
<td>Combined</td>
</tr>
<tr>
<td>3</td>
<td>10 (F)</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Multiple cysts</td>
<td>Mild*</td>
<td>N</td>
<td>None</td>
</tr>
<tr>
<td>4</td>
<td>18 (F)</td>
<td>EH BDC</td>
<td>N</td>
<td>Tail, body</td>
<td>Multiple cysts</td>
<td>Moderate</td>
<td>Bicornuate unicollis</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>32 (F)</td>
<td>IH BDC</td>
<td>N</td>
<td>Tail, body</td>
<td>N</td>
<td>Moderate</td>
<td>N</td>
<td>Combined</td>
</tr>
<tr>
<td>6</td>
<td>44 (F)</td>
<td>N</td>
<td>N</td>
<td>Tail</td>
<td>Multiple cysts</td>
<td>Severe*</td>
<td>N</td>
<td>Intermediate-acting</td>
</tr>
<tr>
<td>7</td>
<td>39 (F)</td>
<td>EH BDC</td>
<td>Cyst</td>
<td>Tail, body</td>
<td>Multiple cysts</td>
<td>No</td>
<td>Bicornuate unicollis</td>
<td>Short-acting</td>
</tr>
<tr>
<td>8</td>
<td>17 (M)</td>
<td>N</td>
<td>N</td>
<td>Tail, body</td>
<td>Multiple cysts in right kidney</td>
<td>No</td>
<td>—</td>
<td>None</td>
</tr>
<tr>
<td>9</td>
<td>27 (F)</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Multiple cysts, angiomyolipoma</td>
<td>No</td>
<td>Bicornuate unicollis</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>19 (F)</td>
<td>N</td>
<td>N</td>
<td>Tail, body</td>
<td>One cyst, right kidney absent</td>
<td>No</td>
<td>N</td>
<td>Combined</td>
</tr>
<tr>
<td>11</td>
<td>37 (F)</td>
<td>IH BDC</td>
<td>N</td>
<td>Tail, body</td>
<td>Multiple cysts</td>
<td>No</td>
<td>N</td>
<td>Combined</td>
</tr>
<tr>
<td>12</td>
<td>22 (M)</td>
<td>N (gallbladder)</td>
<td>N</td>
<td>Tail</td>
<td>Multiple cysts</td>
<td>No</td>
<td>—</td>
<td>None</td>
</tr>
<tr>
<td>13</td>
<td>30 (F)</td>
<td>N</td>
<td>N</td>
<td>Tail, body</td>
<td>Multiple cysts</td>
<td>Kidney transplantation Mild</td>
<td>Bicornuate unicollis</td>
<td>Intermediate-acting</td>
</tr>
<tr>
<td>14</td>
<td>68 (F)</td>
<td>EH and IH BDC</td>
<td>N</td>
<td>Tail</td>
<td>Multiple cysts</td>
<td>No</td>
<td>—</td>
<td>Long-acting</td>
</tr>
</tbody>
</table>

Abbreviations: EH, extrahepatic; F, female; IH, intrahepatic; M, male; N, normal; NA, not available; RI, renal insufficiency.

*At the time of MRI.

*bAt the time of MRI, estimated glomerular filtration rate (millimeters per minute divided by 1.73 m²): mild, 60 to 89; moderate, 30 to 59; severe, 15 to 29; end-stage renal disease, <15.

cLong-acting insulin started at 14 years.

dA splenic cyst.

eLater progressed to moderate.

*fLater progressed to end-stage renal disease, renal transplantation.

*gIntraductal papillary mucinous neoplasialike cystic dilatations of the pancreatic branch ducts.

*hAdenomyomatosis of the gallbladder and pancreas divisum was observed. The horizontal duodenum did not cross the midline at its normal position, a finding suggestive of malrotation. Normal glucose tolerance in oral glucose tolerance test.

*iAfter renal transplantation, cholestatic episode caused by adenomatous tissue near ampulla of Vater.

+jIn addition to the dilated biliary ducts, adenomyomatosis of the gallbladder was observed.

+kA few punctate calcifications in the pancreatic parenchyma were detectable on computed tomography imaging.
findings resembled those of intraductal papillary mucinous neoplasia (Fig. 3).

With renal cysts observed in all but one patient, the radiological findings did not correlate with the severity of renal insufficiency; in eight of 14 (57%) patients, the renal function appeared to be normal, whereas six patients had renal insufficiency of some degree (Table 1). Uterine malformations were common (five of the 11 female patients) (Table 1).

Of 12 patients with data for magnesium concentrations, 10 (83%) have had hypomagnesemia at some stage of the follow-up (Fig. 4), but it was symptomatic in only two patients (one had muscle cramps and one had hypokalemia, despite replacement with potassium chloride). The average (mean of individual medians) concentration of magnesium was 0.66 mmol/L and the lowest concentration was 0.36 mmol/L (reference range $\geq 0.70$ mmol/L). Uric acid concentration was, at least occasionally, elevated in nine of the 14 (64%) patients, but only one had developed symptomatic gout. The highest uric acid concentration was 1.6 times the upper limit of normal (Fig. 4). As suggested by Clissold...
et al. (21), patients with whole-allele deletions of HNF1B seemed to have lower magnesium concentrations, and patients with intragenic mutations had higher uric acid concentrations, but the differences were not statistically significant (Fig. 4).

Discussion

Besides confirming the frequent occurrence of pancreatic hypoplasia, contrast-enhanced MRI and MRCP revealed BDCs in six of 14 HNF1B carriers, which clearly exceeds the reported 1:13,000 to 1:150,000 prevalence in Western populations (30–32). Together with the developmental role of HNF1B in biliary organogenesis (1, 3, 5) and case reports on cholestasis in mutation carriers (23–25), our report confirms a biliary phenotype in human HNF1B disease and shows that such a phenotype is more prevalent than previously reported. Do these findings have clinical implications?

In patients with HNF1B, the combination of reduced β-cell mass (12 of the 14 patients had pancreatic hypoplasia), associated with functional abnormalities in insulin secretion (10), may precipitate diabetes in non-diabetic carriers, or worsen the hyperglycemia in diabetic carriers at initiation of immunosuppressive therapy. Because many immunosuppressive agents (calcineurin inhibitors, mTOR inhibitors, and steroids) inhibit insulin transcription and/or secretion, and steroids decrease insulin sensitivity (33), careful monitoring of plasma glucose after transplantation is fundamental, irrespective of pretransplantation diabetes status of patients with HNF1B. Not surprisingly, the two patients with a kidney transplantation (nos. 6 and 13) showed deterioration of glycemic control during posttransplantation treatment.

The multiple observations of BDCs or choledochal cysts, which are rare cystic or fusiform dilatations of the extrahepatic and/or intrahepatic biliary ducts, was an unexpected finding. Yet, the pathophysiology of BDCs is unclear. The most prevalent theory states that an anomalous pancreaticobiliary junction (APBJ) is associated with reflux of the pancreatic juice, eventually leading to a BDC (30–32). We did not observe an APBJ in any patient (data not shown). Furthermore, primary strictures of the common bile duct may, in part, contribute to the dilatation of the bile ducts (32). Alternatively, BDCs may be ductal plate malformations (34), a theory supported by reports on ductal plate malformations in some neonatal patients with HNF1B (23–26), as well as evidence in mice that inactivation of HNF1B results in such malformations (35).

Traditionally, BDCs are classified according to the classification system proposed by Todani et al (36), but this has been criticized for its complexity and the need for additions, given that not all types of cysts are covered [as reviewed by Katabathina et al (31)]. Only three of our patients’ BDCs had typical morphology for any Todani class. Previously, BDCs were mostly diagnosed in children with a triad of jaundice, abdominal pain, and

Figure 3. T2-weighted axial MRI scans of the pancreas with (a, b) fat saturation and (c) a maximum-intensity projection image of the MRCP images. Aplasia of the pancreatic body and tail was observed in nine patients. One of these patients had cystic dilatations of the pancreatic branch ducts. (a) Patient no. 9, with normal pancreas (arrows). (b) Patient no. 7, in whom only the pancreatic head and uncinate process can be observed (arrow). (c) Patient no. 14, with small cystic dilatations of the pancreatic branch ducts (arrows) consistent with branch duct intrapancreatic mucinous neoplasia. A fusiform BDC of the extrahepatic bile ducts in their entirety (double asterisk) and the right main bile duct (asterisk), consistent with Todani classification type 4a, is also seen.
 palpable mass, but after advances in modern diagnostic imaging, up to 36% of the affected are adults with incidental BDCs or with nonspecific symptoms (30–32). Indeed, excluding posttransplantation and postoperative complications, our cohort included only one patient with a medical history of unspecific, occasional abdominal symptoms. BDCs can result in various complications, including biliary stones, cholangitis, pancreatitis, portal hypertension, liver cirrhosis and fibrosis, as well as spontaneous cyst ruptures. The most severe complication, however, is the risk for cholangiocarcinoma, which increases from 0.7% in children to as high as 15% to 20% in adults (30, 37). Other malignancies (particularly gallbladder cancer) have also been associated with BDCs (30).

Because of their premalignant nature, the majority of extrahepatic BDCs are surgically excised (37, 38). An increasing number of incidental BDCs has led to a debate as to whether only symptomatic or high-risk patients should undergo surgery (30). Unfortunately, an individual risk assessment is not possible. Apart from the association between APBJs and gallbladder cancer (30), no structural or biochemical risk factor has been identified. Is the risk of malignancy of HNF1B-related BDCs similar to the risk of other BDCs? A previously described patient with HNF1B and neonatal cholestasis had two paternal family members with liver cirrhosis and liver cancer, but information on their mutation status or the nature of the cancer was not available (39). The frequent finding of hypoplastic pancreas in HNF1B carriers warrants at least careful consideration of pros and cons of surgically excising the BDCs, given that the surgery usually includes a Roux-en-Y hepaticojejunostomy, with partial removal of the head of pancreas (37, 38), which will potentially lead to deterioration of endocrine and exocrine pancreatic functions that are already impaired in patients with HNF1B. On the other hand, there is no way to accurately predict the individual risk of malignancy, and the biliary anomalies might result in technical challenges in ERCP and increased risk for complications when collecting brush cytology. Indeed, there were technical problems in both of our patients who had undergone ERCP.

In accord with previous reports of increased levels of ALT and aspartate aminotransferase in up to 50% to 75% of patients with HNF1B without apparent liver disease [as reviewed by Chen et al (7)], half of our patients had slightly elevated serum ALT concentrations. Because liver biopsies have rarely been performed and all reported patient series have been small, the etiology remains obscure. Only two of our patients (nos. 6 and 13) were known to have had cholestatic episodes, but in both cases, cholestasis developed after renal transplantation and during immunosuppressive treatment with calcineurin inhibitors. In vitro, calcineurin inhibitors downregulate HNF1B gene transcription and translation, and the downregulation of the nonmutated allele has been associated with posttransplantation cholestasis (28). Thus, a pretransplantation diagnosis of HNF1B disease warrants careful follow-up of hepatic and biliary laboratory parameters, which is crucial for an early diagnosis of more severe forms of cholestasis.

Conclusions

Imaging with contrast-enhanced MRI and MRCP revealed BDCs, also known as choledochal cysts, in six of 14 HNF1B carriers. It is unknown whether these choledochal cysts confer a similar risk for cholangiocarcinoma as BDCs in general. On the basis of this small series of patients, recommendations for routine screening of patients with HNF1B mutations cannot be given. Further studies in larger patient series as well as genetic testing of HNF1B mutations in individuals with BDCs that have resulted in cholangiocarcinoma are needed. In any case, surgical resection involving partial
removal of the head of pancreas poses a significant risk for the deterioration of insulin secretion in these patients, who generally already lack the body and tail of the pancreas. Finally, clinical evaluation of the other disease manifestations associated with HNF1B mutations and/or genetic testing should be considered in patients with BDCs.

Acknowledgments

We thank Dr. Satu Vehkavaara, Dr. Virpi Sipilä, and Dr. Tuula Pekkarinen for the referral of three of the patients. The Botnia Study has also been supported by grants from the Sigrid Juselius Foundation, Foundation for Life and Health in Finland, Finnish Medical Society, Ollqvist Foundation, Närpes Health Care Foundation, as well as by the Municipal Heath Care Center and Hospital in Jakobstad and Health Care Centers in Vasa, Närpes, and Korsholm. The skillful assistance of the Botnia Study Group is gratefully acknowledged.

Disclosures: The authors have nothing to disclose.

References


